Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Novel Potent TIM-3 Inhibitors were discovered in ChemDiv’s collection.

Novel Potent TIM-3 Inhibitors were discovered in ChemDiv’s collection.

The ChemDiv’s proprietary library of chemically diverse small molecule compounds was demonstrated to be a source of selective inhibitors targeting specific check points was found out in a recent preclinical study. In a collaborative effort, researchers from the Molecular Imaging Innovations Institute at Weill Cornell Medicine and Freie Universitaet Berlin used a selective set of the ChemDiv’s small molecule library to study a novel class of drugs engaging with the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Published by Abdel-Rahman et al. in the Journal of Medicinal Chemistry,1 the study highlights the library’s compounds for their exceptional selectivity, affinity, and inhibitory action against TIM-3.

TIM-3 has emerged as a significant therapeutic target for chemotherapeutics against Acute Myeloid Leukemia (AML). The encouraging outcomes of the study confirm that our in-depth research, focusing on the molecular interactions of drug compounds with specific target moieties, unveils their potential to disrupt crucial pathways in the AML cells. ChemDiv's expertise in medicinal chemistry and drug design was instrumental in this discovery, showcasing our ability to pioneer novel treatments in the highly complex field of cancer therapies. Meanwhile, ChemDiv’s team of expert scientists continues to make efforts to expand our compound library, known for its remarkable chemical diversity and the highest quality of medicinal chemistry. 

About ChemDiv

ChemDiv is committed to partnering in the discovery and development of groundbreaking therapies, utilizing its unique chem-bio platforms. These include molecular glues, stabilizers, and degraders; covalent and non-covalent binders; and bifunctional molecules for synergistic effects and synthetic lethality. Over the past 30 years, ChemDiv has successfully completed hundreds of lead, candidate, and new drug programs in collaboration with pharma, biotech, and academic partners globally, targeting cancer, neurological, infectious, cardiometabolic, and immune diseases. Learn more at www.chemdiv.com

1 Abdel-Rahman SA, Talagayev V, Pach S, Wolber G, Gabr MT. Discovery of Small-Molecule TIM-3 Inhibitors for Acute Myeloid Leukemia Using Pharmacophore-Based Virtual Screening. J Med Chem. 2023 Aug 24;66(16):11464-11475. doi: 10.1021/acs.jmedchem.3c00960.

0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies